Description: This article discusses the regulatory changes in Bermuda. There is an international initiative to review all insurance regulation by the International Association of Insurance Supervisors IAIS and the International Monetary Fund IMF.

Description: This article is the testimony of the author to the New York State Assembly Standing Committee on Insurance expressing his views about a proposed law to allow a domestic mutual life insurer to reorganize as a stock company that is owned by a mutual holding company.

Description: This article reviews the topics discussed at the December 2004 meeting of the Life and Health Actuarial task force. The covered topics include Actuarial Guideline 38 and Reserves for Variable Annuities C-3 Phase 2 reserves.

Description: Discover the unique challenges and resilience of LGBTQ+ older adults as they navigate aging and retirement in this comprehensive review.

Description: The document is a Call for Proposals issued by the Society of Actuaries Research Institute's Research Executive Committee, outlining the background, purpose, research objectives, suggested topic areas, proposal requirements, evaluation criteria, selection process, submission guidelines, and conditions for funding high-quality research projects related to emerging issues in actuarial practice areas.

Description: Explore the value and cost of prescription drugs, how they should be defined and measured and the effects various stakeholders in the pharmacy ecosystem can have on these factors in the latest webcast. You'll investigate the impact of coverage, formulary and rebate negotiations and related benefit design. Find out how actuaries can answer questions related to the prescription drug industry, in addition to improving the access, quality and affordability of prescription drugs in the United States. Join us for this webcast and come learn about value-based contract design, negotiations, implementation and administration for prescription drugs.

Description: The big event of 2023 is the launch of multiple Humira biosimilars, which began in January with the arrival of Amgen’s Amjevita on the market. The launch of Amjevita kicks off the process of changing the specialty drug marketplace in the United States. The expectation of the full impact of this big event is very hopeful, but there is still uncertainty several months after its beginning. Humira is the highest-selling drug in the world and has been since 2013 (Figure 1)—except for when COVID-19 projects temporarily surpassed it. The world is eagerly awaiting the launch of multiple biosimilar drugs to compete with Humira and hopefully bring more competitive pricing to the benefit of payers and patients everywhere.

Description: The article discusses ACLI's comment letters submitted to Treasury and the IRS in response to the proposed regulations on the Corporate Alternative Minimum Tax and Ranking Member Ron Wyden (D-OR)'s discussion draft of the Protecting Proper Life Insurance From Abuse Act, that would impact the taxation of some to private placement life insurance.

Description: Session 2A: Navigating Medicaid Single Preferred Drug Lists (PDLs) - A Deep Dive

Description: The research provides a modeling framework for assessing the inundation risk of properties and their expected flood damages, thereby laying a foundation for flood insurance pricing. The researchers studied over 50 years of claims data from the National Flood Insurance Program with 2.5 million records and identify property characteristics that predict flood damages for inundated properties. The development of a private flood insurance market benefits from insurers’ ability to better understand and price flood risk. This research takes a closer look at flood risk modeling and flood insurance pricing.